U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146750) titled 'A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants' on Aug. 21.
Brief Summary: This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.
Study Start Date: Aug. 25
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
COMBINATION_PRODUCT: SAR445229
Single dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sanofi
...